, a global innovator in drug delivery platforms, has announced that study program DIAB-A22-1 is expected to begin on schedule today. According to the announcement, this is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes. The company has evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. Strong connections exist between heart disease, hypertension and diabetes, with hypertension twice as frequent in diabetics and hypertensive patients at greater risk of developing diabetes. Diabetes, which prevents the body from making enough insulin and results in abnormal blood sugar levels, is the seventh largest cause of death in the U.S. and there is currently no cure. Investigation of CBD related to diabetes is in early stages with some areas of ongoing research. CBD has shown some ability to reduce the incidence of diabetes in mice.
To view the full press release, visit
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has…
